Moroccan pharmaceutical company “Pharma 5” is expected to introduce the country’s first generic drug fully produced locally using compounds derived from Indian hemp, specifically cannabidiol (CBD), to treat epilepsy, according to news reports.
Named “Cannabidiol Pharma 5,” the medication will meet the highest international health standards to make advanced epilepsy treatment more accessible to patients.
“Pharma 5” has invested MAD 250 million in developing the drug, which is equivalent to the British medication “Epidyolex,” widely used to treat resistant epilepsy. Unlike the original drug, the Moroccan generic version will be significantly more affordable, priced between approximately 12,100 MAD (€1,100) to 15,400 MAD (€1,400), making it accessible to a broader patient base.
Epilepsy is the second leading cause of neurology consultations in Morocco, with an estimated prevalence of 400 cases per 100,000 people.
The initiative is expected to enhance Morocco’s capacity to address epilepsy-related challenges while positioning the country as a leader in the production of cannabidiol-based pharmaceuticals in Africa.